Zevra Therapeutics, Inc. ZVRA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $122.29M+201% | $106.47M+351% | $84.39M+245% | $62.02M+162% | $40.59M+46.5% | ||
| $17.03M+98.4% | $16.48M+122% | $16.33M+103% | $17.39M+195% | $8.59M+187% | ||
| $105.26M+229% | $89.99M+456% | $68.06M+314% | $44.63M+151% | $32M+29.5% | ||
| 86.1%+7.2pp | 84.5%+15.9pp | 80.7%+13.5pp | 72%-3.2pp | 78.8%-10.3pp | ||
| $13.88M-58.0% | $12.74M-69.7% | $18.48M-59.1% | $25.99M-44.1% | $33.08M-23.8% | ||
| $78.85M+22.3% | $77.62M+41.5% | $73.39M+37.4% | $72.66M+68.9% | $64.48M+74.2% | ||
| $2.56M-59.5% | $3.86M-38.1% | $5.16M-4.5% | $6.39M+62.9% | $6.32M+158% | ||
| $92.73M-4.9% | $90.36M-6.8% | $91.86M-6.8% | $98.65M+10.2% | $97.56M+21.3% | ||
| —— | —— | -$87.67M-1.1% | -$119.12M-59.3% | -$71.88M-25.5% | ||
| $7.72M-10.1% | $7.98M+8.5% | $8.22M+39.1% | $8.48M+114% | $8.59M+318% | ||
| $138.83M+4,083% | $149.62M+4,870% | $141.32M— | $140.52M— | -$3.49M— | ||
| —— | —— | —— | —— | —— | ||
| $191.64M— | $148.33M— | $148.33M— | $148.33M— | $0— | ||
| $133.4M+277% | $86.68M+196% | $53.64M+160% | $21.4M+132% | -$75.37M-52.5% | ||
| $9.18M-44.8% | $3.45M-77.6% | $18.32M— | $18.75M+10,494% | $16.62M+50,273% | ||
| $124.22M+235% | $83.23M+179% | $35.33M+139% | $2.64M+104% | -$91.99M-86.0% | ||
| 101.6%+328pp | 78.2%+525pp | 41.9%+408pp | 4.3%+286pp | -226.6%-48.2pp | ||
| $1.99+204% | $1.33+158% | $0.45— | -$0.23— | -$1.92— | ||
| $2.05+207% | $1.37+161% | $0.48+123% | -$0.20+88.4% | -$1.92-45.5% | ||
| 229.8M+20.9% | 223.6M— | 212.6M— | 204.5M— | 190.1M— | ||
| 224.4M+18.1% | 220.1M+23.9% | 211.1M+26.4% | 202.9M+31.9% | 190.1M+30.3% | ||
| $2.56M-59.5% | $3.86M-38.1% | $5.16M— | $6.39M— | $6.32M— | ||
| $1.73M— | -$2.18M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $9.99M+437% | $6.95M+209% | $5.23M+113% | $3.97M+26.2% | $1.86M-58.0% | ||
| $13.88M-58.0% | $12.74M-69.7% | $18.48M-59.1% | $25.99M-44.1% | $33.08M-23.8% | ||
| —— | —— | —— | —— | —— | ||
| -$136K+99.8% | -$57.64M+33.7% | -$87.67M-1.1% | -$119.12M-59.3% | -$71.88M-25.5% | ||
| $2.64M+104% | -$53.59M+33.5% | -$82.33M-1.4% | -$112.56M-58.9% | -$65.4M-19.4% | ||
| $2.64M+104% | -$53.59M+33.5% | -$82.33M-1.4% | -$112.56M-58.9% | -$65.4M-19.4% | ||
| 2.2%+163pp | -50.3%+291pp | -97.6%+234pp | -181.5%+118pp | -161.1%+36.5pp | ||
| -$136K+99.8% | -$57.64M+33.7% | -$87.67M-1.1% | -$119.12M-59.3% | -$71.88M-25.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Zevra Therapeutics, Inc.'s revenue?
- Zevra Therapeutics, Inc. (ZVRA) generated $122.3M in revenue over the trailing twelve months, up 201.3% year over year.
- Is Zevra Therapeutics, Inc. profitable?
- Zevra Therapeutics, Inc. reported $124.2M in net income over the trailing twelve months, a 101.6% net margin.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Gross margin is 86.1% and operating margin is -103.9%, with a 101.6% net margin.
- What is Zevra Therapeutics, Inc.'s earnings per share?
- Zevra Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $1.99.
- Where does Zevra Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
